

# THE LANCET

## Infectious Diseases


### Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.


Supplement to: Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. *Lancet Infect Dis* 2022; published online April 12. [https://doi.org/10.1016/S1473-3099\(21\)00812-4](https://doi.org/10.1016/S1473-3099(21)00812-4).

## Appendix 1. Description of STIs and vaccination series assuming a duration of protection of 6 months

### *Complete vaccination series and assuming a duration of protection of 6 months<sup>1</sup>*



### *Partial vaccination series and assuming a duration of protection of 6 months<sup>2</sup>*




<sup>1</sup>Excludes STIs that occurred between the first and second MenB-4C dose or STIs that occurred <30 days after the second MenB-4C dose where vaccination series was complete


<sup>2</sup>Excludes STIs that occurred <30 days after the single dose where vaccination series was partial

## Appendix 2. Description of STIs and vaccination series assuming a duration of protection of 12 months

### *Complete vaccination series and assuming a duration of protection of 12 months<sup>1</sup>*



### *Partial vaccination series and assuming a duration of protection of 12 months<sup>2</sup>*



<sup>1</sup>Excludes STIs that occurred between the first and second MenB-4C dose or STIs that occurred <30 days after the second MenB-4C dose where vaccination series was complete

<sup>2</sup>Excludes STIs that occurred <30 days after the single dose where vaccination series was partial